Brief: Jiangsu Recbio Technology Says It Got Positive Results For A COVID-19 Vaccine Recov Study In Philippines
23/12/2022 10:22
Dec 23 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* GOT POSITIVE RESULTS FOR SEQUENTIAL BOOSTER VACCINATION
PHASE II
STUDY OF A COVID-19 VACCINE RECOV IN PHILIPPINES
* COMPLETED CONSTRUCTION OF RECOV MANUFACTURING FACILITY AND
PREPARATION FOR COMMERCIAL PRODUCTION
* OBTAINED RELEVANT VACCINE PRODUCTION LICENSE ISSUED BY
REGULATORY AUTHORITIES IN CHINA
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares